Table 1 Demographic and clinical data, received DAA regimen at study groups
| Â | Group I (n = 100) | Group II (n = 20) | p value |
|---|---|---|---|
Age in years | |||
 Mean ± SD (range) | 58.6 ± 6.5 (45–77) | 56.2 ± 6.7 (45–66) | 0.139 |
Gender, no (%) | |||
 Male | 28 (28%) | 9 (45%) |  |
 Female | 72 (72%) | 11 (55%) | 0.133 |
Diabetics, no (%) | 47 (47%) | 5 (25%) | 0.07 |
Hypertensives, no (%) | 32(32%) | 5 (25%) | 0.536 |
Documented IHD, no (%) | 30 (30%) | 4 (20%) | 0.265 |
Cardiac premedication, no (%) | 31 (31%) | 4 (20%) | 0.241 |
Pretreatment LVEF%, no (%) | 46.9 ± 2.5 (40-50) | 65.05 ± 4.4 (58-73) | < 0.001 |
DAA regimen, no (%) | |||
 Dual | 73(73%) | 15(75%) |  |
 Triple | 27(27%) | 5(25%) | 0.854 |